10x Genomics, Inc. (TXG) Earnings
10x Genomics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.23. TXG has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +15.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.29 | $-0.10 | +65.5% | $151M | +3.0% |
| Feb 12, 2026 | $-0.19 | $-0.13 | +31.6% | $166M | +3.5% |
| Nov 6, 2025 | $-0.07 | $-0.22 | -214.3% | $149M | +4.6% |
| Aug 7, 2025 | $-0.35 | $0.28 | +180.0% | $173M | +23.9% |
| May 8, 2025 | $-0.45 | $-0.36 | +20.0% | $155M | +6.6% |
| Feb 12, 2025 | $-0.29 | $-0.40 | -37.9% | $165M | +0.0% |
| Aug 8, 2024 | $-0.47 | $-0.32 | +31.9% | $153M | +2.0% |
| Apr 30, 2024 | $-0.46 | $-0.50 | -8.7% | $141M | -0.9% |
| Feb 15, 2024 | $-0.36 | $-0.41 | -13.9% | $184M | +0.6% |
| Nov 2, 2023 | $-0.45 | $-0.51 | -13.3% | $154M | +1.6% |
| Aug 3, 2023 | $-0.39 | $-0.53 | -35.9% | $147M | +4.9% |
| May 3, 2023 | $-0.38 | $-0.44 | -15.8% | $134M | -3.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Serge mentioned solid sales momentum, a step-change advance in the product roadmap, and strong execution. The launch of Atera, the most significant product introduction in the company's history, enables spatial whole transcriptome analysis with single-cell sensitivity at scale. There was double-digit growth in single-cell and Spatial consumables. Partnerships with AI-focused companies and progress in translational applications were highlighted.
Guidance
Maintain full-year revenue outlook of $600 million to $625 million. Q2 revenue is expected to step down sequentially from Q1, Q3 is anticipated to be broadly similar to Q2, and Q4 will see Atera shipments begin though initial production capacity for Atera will be limited in 2026.
Segment performance
Revenue for the first quarter was $151 million, representing 9% growth over Q1 2025 when excluding non-recurring settlement revenue. Single-cell saw double-digit growth in consumable reaction volumes driven by Flex APEX. Spatial had double-digit growth in consumables revenue driven by Xenium momentum. The new Atera instrument platform was launched, poised to redefine spatial biology with capabilities like whole transcriptome analysis at scale.
Risks & headwinds
Risks include macro environment challenges affecting capital equipment spending, potential margin pressure from Atera instrument launch due to lower instrument margins, and potential cannibalization of existing spatial products as customers wait for Atera.
Analyst Q&A
Q: Patrick Donnelly from Citi asks about Atera funnel and launch impact on portfolio.
A: Serge responds on high customer interest, planned for order dynamics, existing products continue robust.
Q: Matt LaRue from William Blair asks about AI TAM.
A: Serge talks about AI being a structural tailwind, AI's need for large biological data, and AI initiatives driving business.
Q: Doug Schenkel from Wolf Research asks about gross margin and Atera margin impact.
A: Adam says monitoring costs, Atera instrument margins lower, but full-year mid-60s margin expected.
Q: Mason Carrico from Stevens asks about spatial instrument revenue and Atera placements.
A: TAB mentions Q2/Q3 spatial sales decline, Atera Q4 placements around 40 units.
Q: Luke Sergut from Barclays asks about Atera pricing and cannibalization.
A: Serge talks about Atera's significance, removing spatial constraints, existing products still robust.
Q: Dan Brennan from TD Cowan asks about OpEx.
A: Kyle says OpEx down due to disciplined cost management, anticipating roughly flat OpEx going forward.
Q: Kyle Nixon from Canaccord asks about spatial instruments and Q2 guidance.
A: Adam says Q2 low single-digit decline, spatial instruments down due to Atera anticipation.
Q: Michael Riskin from Bank of America asks about Atera manufacturing capacity.
A: Serge says Atera is sophisticated, team working to ramp production.
Q: Subbu Nambi from Guggenheim Securities asks about single-cell pricing.
A: Serge says single-cell launch early, strong trajectory.
Q: Sam Martin from Deutsche Bank asks about Visium.
A: Serge says Visium has place, customers like it, trend towards Xenium with Atera.
Q: Puneet Sudha from WeRank Partners asks about Visium and Atera.
A: Serge says Atera affects Visium, but products have stickiness.
Q: Tycho Peterson from Jefferies asks about clinical adoption of Atera.
A: Serge says biopharma partners encouraged, Atera enables large-scale trials.
Q: Dan Arias from Stifel asks about flex volumes and Atera.
A: Serge says no near-term impact on single-cell, reaction growth across applications